Kornimate/medical-research-clean huggingface dataset:
laser-assisted versus conventional intracytoplasmic sperm injection

Conditions: Infertility; Infertility, Male

Summary: laser-assisted intracytoplasmic sperm injection (icsi) has been suggested as a more effective alterative to conventional icsi when this method of insemination is indicated for patients undergoing in vitro fertilization (ivf). laser-assisted icsi differs from conventional icsi in that a laser is used to drill a small hole through the hard outer coating surrounding an egg before the injection needle containing a single sperm is inserted into the egg. the hole eliminates compression of the egg that normally occurs with conventional icsi, and thus may reduce the chance of damage. laser-assisted icsi is hypothesized to result in increased egg survival, and perhaps improved embryo quality, compared to conventional icsi.


Eligibility criteria:
inclusion criteria: * diagnosis of infertility * scheduled for ivf with icsi exclusion criteria: * retrieval of fewer than 6 mature oocytes

Keywords: in vitro fertilization intracytoplasmic sperm injection oocytes zona pellucida oolemma fertilization preimplantation embryo development
investigate the efficacy of chemotherapy in patients with positive ctdna after surgery and adjuvant chemotherapy for a stage iii colorectal cancer

Conditions: Colon or Upper Rectum Adenocarcinoma

Summary: phase iii multicentric, open-label, randomized study the main objective is to assess the efficacy on time to disease recurrence (ttr) of treating minimal residual disease diagnosed by the presence of ctdna after full treatment (surgery + chemotherapy) in stage iii or high-risk stage ii colon or upper rectum adenocarcinoma


Eligibility criteria:
inclusion criteria: * fully resected stage iii or high-risk stage ii colon or upper rectum adenocarcinoma previously treated by standard adjuvant chemotherapy or peri-operative chemotherapy (folfox or capox) for either 3 or 6 months based on local multidisciplinary meeting, and on tncd recommendations * positive ctdna screening (methylation) and confirmation (ngs) on samples collected at the 3- or 6 months follow-up visit post-adjuvant chemotherapy * patients ≥ 18 years and ≤ 80 years (provided the score of the g8 geriatric questionnaire is \>14 for patients 70 years or older) * subjects with who performance status \< 2 * no documented disease using tap ct-scanner and liver mri in the case of contra-indication to dye contrast (or tep-scanner may be also used in addition depending on physicians' choice and local availabilities). * adequate haematological function: with neutrophils ≥ 1,500 /mm3, platelet count ≥ 100,000/mm3, hemoglobin ≥ 9 g/dl (5,6 mmol/l) total bilirubin ≤ 1.5 x uln (upper limit of normal) asat and alat ≤ 2.5 x uln alkaline phosphatase ≤ 2.5 x uln creatinine clearance ≥50 ml/min according mdrd (modification of diet in renal disease) * available tumor sample for ngs analysis * signed written informed consent obtained prior to any study specific procedures * patient affiliated to a social security scheme exclusion criteria: * patients already treated with trifluridine tipiracil or irinotecan in the past 5 years * uncontrolled intercurrent illness * previous malignancies other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell carcinoma of the skin, unless there has been a disease-free interval of at least 3 years * pregnant or breastfeeding women, women of childbearing age not having had a negative pregnancy test * any known specific contraindication or allergy to the treatments used in the study† * total or partial dihydropyrimidine dehydrogenase (dpd) deficiency (uracilemia \> 16ng/ml) * known gilbert's disease (ugt1a1\*28 genotype) * in case of concomitant use with st john's wort related to irinotecan * in case of bowel obstruction according related to irinotecan * in case of recent concomitant treatment with brivudine, related to fluorouracil. * participation to another interventional study for postoperative therapy * persons deprived of liberty or under guardianship or incapable of giving consent * any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol or follow-up schedule.
deep brain stimulation (dbs) for alzheimer's disease

Conditions: Alzheimer Disease

Summary: background: alzheimer disease (ad) is a debilitating brain disorder that affects over 4.75 million people in the us and canada. people with ad have difficulty remembering general facts and previously experienced autobiographical events. animal and human research demonstrates that this type of memory depends on neural function within specific brain areas, and that it may be possible to enhance memory with electrical stimulation of these brain areas. we have recently shown that deep brain stimulation (dbs) of a brain area called the fornix enhances memory in a human. hypotheses: we hypothesize that fornix dbs will safely enhance memory in early ad patients by activating memory circuits in the brain. methods: six early ad patients will take part in a phase i clinical study over a 1-year period. the study involves bilateral fornix dbs implantation, detailed neuropsychological and neurological testing, and brain imaging to detect alterations in brain activity induced by stimulation. these assessments will occur one month before surgery, then again at one month, 6 months, and 12 months after surgery.


Eligibility criteria:
inclusion criteria: * men and women aged 40 to 80 years old, who * satisfy the diagnostic criteria for probable ad, * have received the diagnosis of ad within the past 2 years, * have a cdr of 0.5 or 1.0, and * score between 20 and 28 on the mini mental state examination exclusion criteria: * pre-existing structural brain abnormalities, * other neurologic or psychiatric diagnoses, or * medical comorbidities that would preclude them from undergoing surgery
carpal tunnel syndrome - randomized clinical trial evaluating effectiveness of ultrasound in corticosteroid injection

Conditions: Carpal Tunnel Syndrome

Summary: the objective of this study is to evaluate the efficacy of ultrasound guided corticosteroid injection in reducing symptoms caused by carpal tunnel syndrome.

corticosteroid injection is routinely given for treating carpal tunnel syndrome. the objective of this study is to evaluate the efficacy of ultrasound guided corticosteroid injection in reducing symptoms caused by carpal tunnel syndrome. in this randomised clinical trial, 50 patients with both a clinical and electromyographic diagnosis of mild to moderate carpal tunnel syndrome will be recruited from the centre hospitalier universitaire de sherbrooke (chus). subjects will be randomised to ultrasound guided or blind injection groups. all subjects will receive 40 mg of methylprednisolone. the primary outcome will be the boston carpal tunnel syndrome questionnaire - symptom severity scale at baseline and 3 months post injection. both subjects and assessors will be blinded.

Eligibility criteria:
inclusion criteria: * aged 18 to 65 * understanding written and spoken french * diagnostic of carpal tunnel syndrome : classic of probable based on the katz hand diagram and mild to moderate based on the electrodiagnosis studies exclusion criteria: * carpal tunnel injection in the last 6 months * constant symptoms in medial nerve area * thenar eminence atrophy * absolute contraindication to corticosteroid injection : infective arthritis, bacterial endocarditis, local cellulitis of skin infection, coagulopathy, corticosteroid or latex allergy * secondary diagnosis based on the ultrasound : arthrosynovial cyst, flexor tenosynovitis, ganglion * known cognitive disorder * anticoagulant therapy * diseases known to cause carpal tunnel syndrome : diabetes mellitus, hypothyroidism, connective tissue disease, rheumatic disease and moderate or severe chronic renal impairment * radiculopathy * polyneuropathy * pregnancy * ancient ipsilateral wrist fracture * ancient ipsilateral wrist surgery

Keywords: corticosteroid ultrasound guided injection
a study of glaucoma therapy to treat open-angle glaucoma or ocular hypertension

Conditions: Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to compare the intraocular pressure (iop)-lowering efficacy and safety of two combination products in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * 18 or older. * diagnosis of glaucoma or ocular hypertension. * other protocol-defined inclusion criteria may apply. exclusion criteria: * under 18. * other protocol-defined exclusion criteria may apply.
a phase ii study of capecitabine and docetaxel in previously untreated advanced non-small cell lung cancer patients

Conditions: Lung Cancer; Non-Small-Cell Lung Carcinoma

Summary: this study will determine the objective response rate in chemotherapy naive non-small cell lung cancer patients with advanced disease.

rationale: docetaxel has some efficacy against non-small cell lung cancer (nsclc). this drug is food and drug administration approved in combination with cisplatin (platinol) for the treatment of unresectable, locally advanced or metastatic nsclc in patients who have not previously had chemotherapy for this condition. docetaxel is also approved for second line treatment of metastatic nsclc. research indicates that capecitabine, in combination with docetaxel, has efficacy against nsclc. capecitabine appears to have anti-cancer activity through several enzymes. this drug is metabolized in the body to another agent called 5-fu. during this conversion process, 5-fu requires thymidine phosphorylase (tp), a cellular characteristic associated with tumor growth. there are higher levels of tp expression in tumors as compared to normal tissue. the drug administration schedule in this study is designed to optimize efficacy against the tp target through both docetaxel and capecitabine. this study will measure biological changes to tp and other enzymes to help researchers gain more information about how capecitabine and docetaxel works against nsclc. purpose: this study will evaluate the efficacy of docetaxel and capecitabine in patients with previously untreated advanced nsclc. tests related to tumor biology will be conducted before and during study treatments and correlated with patient responses to therapies. treatment: patients in this study will receive docetaxel and capecitabine. docetaxel will be administered through intravenous infusions. capecitabine will be provided through oral pills. a four-week period constitutes one cycle. docetaxel will be given weekly for three weeks followed by one week of rest. capecitabine will be taken twice daily on days 5 through 14 of the treatment cycle. several tests and exams will be given throughout the study to closely monitor patients. treatments will be discontinued due to disease growth or unacceptable side effects.

Eligibility criteria:
inclusion criteria: * must have advanced nsclc * no prior chemotherapy * eastern cooperative oncology group(ecog)performance status:0 or 1 * must have measurable disease (recist criteria) * life expectancy of at least 12 weeks * adequate organ function including exclusion criteria: * pregnant or lactating women * psychiatric disorders that would interfere w/consent or follow-up * patients with uncontrolled diabetes mellitus, defined as random blood sugar \> 250mg/dl.

Keywords: previously untreated advanced
behavioral smoking cessation treatment - 1

Conditions: Tobacco Use Disorder

Summary: our primary goal is to examine the effectiveness of a multi-factor maintenance treatment strategy in promoting longer-term smoking abstinence. we will also conduct secondary analyses of mediators and moderators of treatment response.

400 adult smokers will be randomized. our primary goal is to examine the effectiveness of a multi-factor maintenance treatment strategy in promoting longer-term smoking abstinence. all smokers will receive the same "acute phase treatment" that combines nicotine patch, bupropion and intensive self-regulatory skills training. nicotine patches will be provided for 8 weeks and bupropion and skills training will be provided for of 9 weeks. participants will then enter a "maintenance treatment phase" during which half (n=200) will receive three individualized relapse prevention training sessions spread over a 12 week period. they will also receive 12 weeks of self-administered rpt administered via written treatment modules. finally, telephone counseling will be provided in conjunction with an interactive voice response system (ivr) that will allow early detection of smoking "slips" and rapid response by treatment staff. the other half (n=200) will be assigned to a control condition that consists of three counselor-led sessions of "supportive therapy" spread over a 12 week period. p

Eligibility criteria:
inclusion criteria: * healthy adult cigarette smokers smoking at least 10 cigarettes per day exclusion criteria: * currently pregnant * currently breastfeeding * currently diagnosed with a seizure disorder, major depression, liver disease, kidney disease, congestive heart failure * history of a seizure, seizure disorder, significant head trauma or central nervous system tumor * family history of seizures * currently using intravenous drugs * currently using any drugs (marijuana, alcohol, cocaine, opiates, stimulants, etc.) on a daily basis * currently using any over-the-counter stimulants and anorectics (diet pills) * currently on bupropion (wellbutrin, wellbutrin sr) or other antidepressants, monoamine oxidase inhibitors, antipsychotics, benzodiazepines, theophylline, systemic steroids or levodopa * currently on nrt or bupropion (zyban) * current or past diagnosis of anorexia nervosa or bulimia nervosa * previous allergic response to bupropion or nrt * previous failed quit attempt using nrt and bupropion in combination
use of music in reducing pain during outpatient hysteroscopy in primarily infertile patients

Conditions: Hysteroscopy

Summary: the aim of this study is to demonstrate the value of music in outpatient hysteroscopy on patients' level of pain and satisfaction in primarily infertile patients.


Eligibility criteria:
inclusion criteria: * women with primary infertility requiring a diagnostic hysteroscopy as a part of an infertility diagnosis workup exclusion criteria: * women with suspected pregnancy heavy vaginal bleeding recent pelvic infection those who received analgesics prior to oh a concomitant neurologic disease that could affect the correct evaluation of pain
an efficacy and safety study of topiramate in the treatment of alcohol dependence

Conditions: Alcoholism

Summary: the purpose of this study is to evaluate the safety and effectiveness of topiramate compared to placebo in patients with alcohol dependence.

the impact of alcoholism can be reduced through effective treatments, which may include medical, psychological, and social interventions. the main goals of alcohol-dependence treatment are to assist patients in avoiding alcohol, developing better strategies for managing stress, and improving self-esteem and quality of life. studies have demonstrated that treatments for alcohol use disorders can be effective, but their effectiveness is often limited. although the optimal goal of treatment should be total abstinence, even patients who are unable to achieve this goal may still benefit from treatments leading to a reduction in drinking. medications are commonly used in other addictive disorders, such as nicotine and opioid dependence, suggesting that this intervention could be useful in the treatment of alcohol dependence. this is a randomized, double-blind, flexible dose study to determine if topiramate, a prescription medication approved by the food \& drug administration for the treatment of epilepsy and the prevention of migraine, administered at a dose of 300mg per day or the subject's maximum tolerated dose, is safe and effective compared with placebo in patients with alcohol dependence. the study hypothesis is that topiramate will be more effective than placebo in reducing the percentage of heavy drinking days (5 or more standard drinks per day for men and 4 or more standard drinks per day for women) in patients with alcohol dependence. the patients will receive topiramate tablets (25mg and/or 100mg) or matching placebo. study medication is taken in increasing doses starting at 25 mg/day up to 300 mg per day (or maximum tolerated dose) during the first 6 weeks and the achieved dose is maintained for an additional 8 weeks.

Eligibility criteria:
inclusion criteria: * have a current diagnosis of alcohol dependence * drink an average of 28 or more standard drinking units/week for women or 35 or more standard drinking units/week for men * have a desire to stop drinking completely or to reduce alcohol consumption with the possible long-term goal of abstinence * have a body mass index of 18 or more * sexually active women capable of having children must be using an acceptable method of birth control * must be in generally good health. exclusion criteria: * no current or recent (within 6 months) diagnosis of other substance abuse or dependence * no inpatient or outpatient counseling for alcohol dependence other than alcoholics anonymous within 4 weeks * not more than 4 past failed inpatient treatments attempts for alcohol dependence * no other psychiatric disorder that requires treatment with medication or therapy * no current probation or parole requirement or legally mandated requirement to participate in an alcohol treatment program.

Keywords: alcoholism alcohol dependence medication treatment.
clinical investigation of the safety and performance of model 690ad and model 690ady monofocal intraocular lens implantation

Conditions: Cataract; Pseudophakia; Intraocular Lens Complication; Intraocular Lens Opacification

Summary: medicontur hydrophilic posterior chamber monofocal intraocular lens (iols) are indicated to improve vision at far distance in adults with cataract and/or ametropia (hyperopia, myopia), secondarily to removal of the crystalline lens. the intraocular lens is intended to be surgically implanted into the eye with the purpose of restoring optical function in the aphakic eye to provide an optical system with high predictability of the precalculated dioptric power. the study will be performed partially as a retrospective study with patients enrolled who had been implanted with 690ad or 690ady iols mono- or binocularly between september 2021 - march 2022. data from five visits will be collected: * baseline preoperative (maximum 90 days prior to surgery)- retrospective * iol implantation day 0 - retrospective * postoperative visit at day 1 (+/- 0 days) - retrospective * postoperative visit at 1 month (+/- 2 weeks) - retrospective * postoperative visit at 12 months (+/- 3 months) - consent and prospective visit


Eligibility criteria:
inclusion criteria: * adult males or females above 18 years of age; * pseudophakic patients implanted with 690ad or 690ady monofocal iols (implanted between september 2021 - march 2022); * diagnosis of cataract and/or ametropia (hyperopia, myopia); * subject who has signed an informed consent form. * patients who have participated in all visits that are subject to retrospective data collection. exclusion criteria: * - patients who are not targeted to emmetropia. * patients with the following condition(s) at the time of the baseline visit: * corneal astigmatism \> 1.0 diopter * uncontrolled diabetic retinopathy * iris neovascularization * congenital eye abnormality * uncontrolled glaucoma * pseudoexfoliation syndrome * amblyopia * uveitis * amd (advanced amd) * retinal detachment * prior ocular surgery in personal medical history * previous laser treatment * corneal diseases * severe retinal diseases (dystrophy, degeneration) * high myopia * inadequate visualization of the fundus on preoperative examination * patients deemed by the clinical investigator because of any systemic disease * pregnancy * eye trauma in medical history * current use of systemic steroids or topical ocular medication * patients with any eye condition that could affect vision in the opinion of the investigator at the time of the 12-month follow-up: (corneal ectasia, retinal diseases, glaucoma, uveitis, dry eye or amblyopia, etc.);
primary non-invasive cardiac computed tomography versus routine invasive angiography prior to tavi

Conditions: Severe Aortic Stenosis; Transcatheter Aortic Valve Implantation

Summary: this pilot study is a prospective, randomized, open-label trial that aims to assess the feasibility of comparing a primary computed tomography/cardiac computed tomography angiography (ct/ccta) strategy (test arm) to a strategy combining routine use of ct/ccta and invasive ca (control arm) prior to a transcatheter aortic valve implantation (tavi) procedure. the study will also estimate the rate of composite coronary adverse events (myocardial infarction, post procedural coronary revascularization and cardiovascular mortality) between the two arms at 90 days follow-up. the primary endpoint will be the feasibility of recruitment and compliance with the study protocol at 2 sites in canada and 1 site in denmark. additional clinical endpoints including: all-cause death at 90 days post procedure, myocardial infarction at 90 days post procedure, unplanned pci or cabg at 90 days post procedure, stroke at 90 days post procedure, ca and pci related cumulative vascular complications events. this information will be used to inform the design of the definitive efficacy trial.


Eligibility criteria:
inclusion criteria: * severe aortic stenosis (peak transvalvular gradient of ≥ 40mmhg on tte or stress echo, aortic valve area of \< 1.0cm2) * symptoms suggestive of aortic stenosis (dyspnea, syncope, angina) * eligible for tavi (upon evaluation by a multidisciplinary team composed of at least one interventional cardiologist and one cardiothoracic surgeon) exclusion criteria: * severe renal dysfunction glomerular filtration rate \< 30 ml/min. * severe left ventricular dysfunction lvef ≤ 30% * recent coronary angiography ≤ 6months from randomization * recent pci ≤ 6months from randomization * recent or active acute coronary syndrome (new or worsening angina with or without positive biomarkers or ecg changes).
children's activities and social participation

Conditions: Child Development Disorder

Summary: the goal of this observational study is to learn the perception of caregivers about the limitations of activities, and the restriction in the social participation of children who are in neurofunctional physiotherapy. the main questions it aims to answer are: * what is the ability to perform tasks, and * how is the social participation of children with atypical motor development? participants will answer two of three questionnaires: * the participation and environment measure - children and youth or the young children's participation and environment measure, depending on the age of their child .the pediatric evaluation of disability inventory - pedi.

the limitation in the execution of activities and tasks, as well as the restriction in the social participation of children considered atypical are considered biopsychosocial aspects of health according to the model of the international classification of disability and health functionality (icf). the perception of the difficulties and limitations in the execution of the tasks, the barriers and facilitators of the environments and the participation and its restrictions, can be important to follow minimal or expressive improvements, indicate important changes in the environment and favor positive changes in the lives of children.

Eligibility criteria:
inclusion criteria: * legal guardians of children aged up to 11 years and 11 months with motor disability * most be in physio-therapeutic care at the school clinic on the realengo campus of the federal institute of education, science and technology of rio de janeiro. exclusion criteria: * guardians of children with a health condition associated with the nervous system without motor limitations * other health conditions.

Keywords: icf child development social participation child